Vicore to Present at Upcoming Investor Conferences
28 augusti, 08:00
28 augusti, 08:00
Stockholm, August 28, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following conferences:
The company’s management team will also be available for meetings at the conferences. Interested parties may access the webcast replay on the Events & Presentations page of Vicore’s website for 90 days following the conclusion of the event.
For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
The company’s shares are listed on Nasdaq Stockholm’s main market (VICO). www.vicorepharma.com
Attachments
Vicore to Present at Upcoming Investor Conferences
28 augusti, 08:00
Stockholm, August 28, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following conferences:
The company’s management team will also be available for meetings at the conferences. Interested parties may access the webcast replay on the Events & Presentations page of Vicore’s website for 90 days following the conclusion of the event.
For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
The company’s shares are listed on Nasdaq Stockholm’s main market (VICO). www.vicorepharma.com
Attachments
Vicore to Present at Upcoming Investor Conferences
Krypto
Krypto
1 DAG %
Senast
Castellum
Igår, 17:32
Här är de 15 mest blankade aktierna
OMX Stockholm 30
1 DAG %
Senast
2 625,70